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Abstract
Background: Valproic acid (VPA) has demonstrated potential as a therapeutic candidate for spinal muscular atrophy (SMA)
in vitro and in vivo.
Methods: Two cohorts of subjects were enrolled in the SMA CARNIVAL TRIAL, a non-ambulatory group of ‘‘sitters’’ (cohort 1)
and an ambulatory group of ‘‘walkers’’ (cohort 2). Here, we present results for cohort 1: a multicenter phase II randomized
double-blind intention-to-treat protocol in non-ambulatory SMA subjects 2–8 years of age. Sixty-one subjects were
randomized 1:1 to placebo or treatment for the first six months; all received active treatment the subsequent six months.
The primary outcome was change in the modified Hammersmith Functional Motor Scale (MHFMS) score following six
months of treatment. Secondary outcomes included safety and adverse event data, and change in MHFMS score for twelve
versus six months of active treatment, body composition, quantitative SMN mRNA levels, maximum ulnar CMAP amplitudes,
myometry and PFT measures.
Results: At 6 months, there was no difference in change from the baseline MHFMS score between treatment and placebo
groups (difference=0.643, 95% CI=21.22–2.51). Adverse events occurred in .80% of subjects and were more common in
the treatment group. Excessive weight gain was the most frequent drug-related adverse event, and increased fat mass was
negatively related to change in MHFMS values (p=0.0409). Post-hoc analysis found that children ages two to three years
that received 12 months treatment, when adjusted for baseline weight, had significantly improved MHFMS scores (p=0.03)
compared to those who received placebo the first six months. A linear regression analysis limited to the influence of age
demonstrates young age as a significant factor in improved MHFMS scores (p=0.007).
Conclusions: This study demonstrated no benefit from six months treatment with VPA and L-carnitine in a young non-
ambulatory cohort of subjects with SMA. Weight gain, age and treatment duration were significant confounding variables
that should be considered in the design of future trials.
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Spinal muscular atrophy (SMA) is an autosomal recessive motor
neuron disease and a leading cause of infant and childhood
mortality. [1–6] More than 95% of affected individuals demon-
strate a homozygous deletion/mutation involving exon 7 in SMN1
(survival motor neuron 1), resulting in the biochemical deficiency
of the SMN protein, part of a complex that functions in the
assembly of small nuclear ribonucleoprotein particles (snRNP).
[7,8] A genomic duplication at this locus has produced a nearly
identical gene, SMN2 (survival motor neuron 2) that differs from
SMN1 by a nucleotide substitution that promotes exon 7 exclusion,
thus producing only a fraction of the identical full length protein.
Phenotypic variation in SMA correlates with the number of SMN2
gene copies and the level of SMN protein in cells [9–15].
Because all SMA patients have 1 or more SMN2 gene copies,
small molecule compounds that target SMN2 to produce increased
quantities of full-length SMN protein from the existing SMN2
gene(s) are attractive therapeutic candidates. Valproic acid (VPA),
a histone deacetylase (HDAC) inhibitor, directly increases SMN
expression in SMA patient-derived cell lines in vitro. [16,17]
Preliminary in vivo data in humans demonstrates up-regulation of
SMN2 expression in about one-third of SMA subjects via
inhibition of HDAC2 and also appears to alter splicing to increase
SMN7 inclusion and thus full-length SMN protein. [18,19] VPA
has also been demonstrated to have neuroprotective properties on
glutamate-induced excitotoxicity via up-regulation of alpha-
synuclein and increases neurite outgrowth in vitro. [20,21] VPA
treatment has been demonstrated to increase survival in animal
models of motor neuron disease including amyotrophic lateral
sclerosis and SMA. [22–24] In an SMA mouse model, VPA
treatment resulted in improved gross motor function, larger
evoked motor potentials, less degeneration of spinal motor neurons
and improved neuromuscular junction innervation in treated
animals compared to age-matched controls [24]. Three open label
trials of VPA in human subjects have been published to date, all
indicating a possible modest benefit in strength and/or motor
function [25–27].
As children with SMA may have a limited carnitine synthetic
capacity due to significantly diminished skeletal muscle mass, and
VPA is known to inhibit carnitine transport and deplete carnitine
levels by binding to VPA metabolites, we elected to combine VPA
therapy with sufficient supplemental carnitine to avoid concerns
about a confounding effect of carnitine depletion. This decision
was influenced by data from our open label VPA trial, which
indicated an increased suspectibility in SMA subjects to carnitine
depletion with VPA treatment [27].
Our primary objective was to assess potential benefit for
improving motor function in a young non-ambulatory cohort of
children with SMA in a randomized double-blind placebo-
controlled clinical trial. Additional objectives were to further
assess the safety of VPA in children with SMA, to assess
performance of selected outcome measures for use in a multi-
center clinical trials setting and to look for evidence that would
support a biologic effect of VPA in these subjects, such as changes
in SMN expression, electrophysiologic outcomes, or both.
Methods
Ethics Statement
Written informed parental consent (subjects ,18 years) and
assent (subjects $7 years) were obtained for all subjects. The study
was approved by the University of Utah Institutional Review
Board (IRB) and at each participating clinical trial site (University
of Wisconsin-Madison Health Sciences; Wayne State University;
Ohio State Biomedical; Johns Hopkins Medical and Ste Justine
Hospital.
Trial Design
The SMA CARNI-VAL trial was a multi-center phase II trial of
CARNItine and VALproic acid in patients with spinal muscular
atrophy. This trial consisted of two parallel multi-center studies,
targeting different SMA cohorts (Clinicaltrials.gov ID
NCT00227266). The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1. Part 1 was a prospective double
blind, placebo-controlled randomized intention-to-treat protocol
to assess safety and efficacy of VPA and L-carnitine in non-
ambulatory SMA type II or III ‘‘sitters’’ 2–8 years of age (cohort
1). Part 2 was a parallel open label trial in SMA type II or III
‘‘standers and walkers’’ 3–17 years of age (cohort 2). In this paper,
we review objectives, methods and results only for Part 1.
Study population
We prospectively enrolled 61 non-ambulatory SMA children at
six centers in North America. The progress of all participants
through the trial is diagrammed in Figure 1. Inclusion and
exclusion criteria are indicated in Figure 2.
Study procedures
All subjects completed two baseline visits within a two to six
week period. Following the second visit, subjects were randomized
to either the placebo arm (group 1) or the treatment arm (group 2).
There were 31 subjects randomized to the placebo arm and 30
subjects randomized to the active treatment arm (Figure 1).
Placebo was provided for both L-carnitine and VPA. Subjects and
investigators remained blinded for the duration of the study. At the
six-month visit, subjects in group 1 were switched to active
treatment for the second six-month period, and those in group 2
continued on study medication for an additional 6 months. Thus,
half of the children received treatment for the last 6 months of the
study, and half received active treatment for the full 12 months.
This trial design was intended to improve trial enrollment and
compliance with the protocol, as focus group discussions with
parents of eligible children indicated significant reluctance to
enroll in a trial of a licensed drug in which there was a 50% chance
of receiving only placebo. Nonetheless, extension of the trial to 12
months in this manner was thought to be potentially useful to
study both the benefit, and burden, of longer treatment duration.
Abbott Pharmaceutical provided VPA and placebo, and Sigma-
Tau Pharmaceutical provided L-carnitine, at no cost. Divalproex
sodium coated particles (DepakoteH sprinkle capsules, 125 mg) or
matched placebo was administered in divided doses two to three
times daily sufficient to maintain overnight trough levels of 50–
100 mg/dL. L-carnitine (or matched placebo, 100 mg/ml liquid)
was dosed at 50 mg/kg/day, to a maximum of 1000 mg, divided
into two daily doses.
Treatment assessments were performed at 3 (V1), 6 (V2) and 12
(V3) months. Laboratories were performed at baseline, 2–3 weeks
following initiation, at each treatment visit and midway between
V2 and V3 visits, and included a basic chemistry profile, CBC
with platelets, transaminases, carnitine profile, amylase, lipase and
trough VPA levels. An un-blinded medical monitor, who also
reviewed subjects’ blood tests and adverse events, performed
dosing adjustments. Similar adjustments were made for subjects in
the placebo group to preserve blinded status of participants.
Contact was possible between the unblinded medical monitor and
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avoid unblinding of the site investigator, parents and patient.
Outcome measures
Primary outcome measures included laboratory safety data,
adverse event data and efficacy as measured by change from baseline
Modified Hammersmith Functional Motor Scale (MHFMS) scores
following six months of treatment versus placebo. Secondary
outcome measures included change from baseline MHFMS score
following 12 versus 6 months treatment, estimates of innervation via
maximum ulnar compound muscle action potential (CMAP), dual-
energy X-ray absorptiometry (DEXA), evaluation of body compo-
sition and bone density, quantitative assessment of SMN mRNA;
evaluation of quality of life using the Pediatric Quality of Life
Inventory (PedsQL) and for children five years and older, change
from baseline measures of pulmonary function and muscle strength
via handheld myometry at 6 and 12 months.
Gross motor function was assessed with the MHFMS. This scale
was previously modified for use in a research setting but contains
the same 20 gross motor function items as the original clinical scale
(complete protocol available at http://smaoutcomes.org). [28–29]
Degree of innervation by the ulnar nerve in the hypothenar muscle
group of the hand was estimated using maximum ulnar
CMAP amplitude (complete CMAP protocol available at http://
smaoutcomes.org). In children five years and older, myometry
Figure 1. Consort flow diagram.
doi:10.1371/journal.pone.0012140.g001
Figure 2. Inclusion and exclusion criteria.
doi:10.1371/journal.pone.0012140.g002
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flexion, and for right and left knee extension, at each visit using the
Lafayette Instrument MMT System Model 01163 myometer with
a positioning method as previously described. [30,31] If any
measure was more than 10% different than any of the other two
measurements, then a fourth measurement was performed. The
summary statistic was the average of either three or four
measurements taken during a visit for both the right and left
elbow and knee. [32–34] In children five years and older,
pulmonary function testing (PFT) was performed in an accredited
pediatric laboratory and included forced vital capacity (FVC),
forced expiratory volume in one second (FEV1) and maximum
expiratory and inspiratory pressures (MEP, MIP). Dual-energy X-
ray absorptiometry (DEXA) scanning for bone density and body
composition was performed at the Salt Lake City, Madison and
Columbus sites. Norland DEXA XR-36 software version 3.3.1 for
small subjects was used to assess whole body composition and bone
mineral density (BMD) and bone mineral content (BMC). Quality
of life (QOL) was assessed using the PedsQL [35]. The same
parent completed the PedsQL at each visit and children five years
of age and older completed the age-appropriate PedsQL. The
questionnaire is scored on a 0 to 100 scale such that a higher score
indicates better QOL.
SMN2 copy number was determined as previously described.
[11] Whole blood was drawn into PAXgene tubes at baseline and
each visit and quantitation of full length SMN (flSMN) and
SMND7 mRNA transcripts was performed as previously de-
scribed. [27,36] Human RPLPO (large ribosomal protein) and
PGK1 (phosphoglycerate kinase 1) were run as endogenous
controls. Subjects missing baseline data or who had incomplete
visit data were excluded from this analysis. Results are reported as
relative amounts of flSMN or SMND7 transcripts normalized
against the relative amount of RPLPO.
Table 1. Baseline demographics by treatment arm.
Group 1 Placebo
1 Group 2 CARNI-VAL
2 Total
Characteristic N=31 (%) N=30 (%) N=61 (%)
Age (years)
Mean 4.4 4.3 4.3
SD 1.9 2.1 2.0
Median 4.1 3.7 3.8
Range 2.1–7.9 1.8–8.7 1.8–8.7
Gender
Female 11 (35.5) 17 (56.7) 28 (45.9)
Male 20 (64.5) 13 (43.3) 33 (54.1)
Ethnicity
Hispanic 2 (6.5) 1 (3.3) 3 (4.9)
Non-Hispanic 29 (93.5) 27 (90.0) 56 (91.8)
Unknown 0 (0.0) 2 (6.7) 2 (3.3)
Race
Asian 1 (3.2) 2 (6.7) 3 (4.9)
African American 1 (3.2) 0 (0.0) 1 (1.6)
White 26 (83.9) 25 (83.3) 51 (83.6)
Unknown 3 (9.7) 3 (10.0) 6 (9.8)
1= placebo group received matched placebo for both medications, L-carnitine and VPA.
2=active treatment group received both L-carnitine and VPA.
doi:10.1371/journal.pone.0012140.t001
Table 2. MHFMS score – Change from baseline to 6 months
(Phase I).
Group 1
Placebo
1
Group 2
CARNI-VAL
2
Endpoint N=31 N=30 p-value
Last Screen Value (S2)
Mean 20.0 16.6 0.1373
SD 9.3 8.7
Median 18.0 16.5
Range 3.0–38.0 3.0–36.0
6 Month Visit (V2)
Mean 20.6 16.8 0.0790
SD 8.1 7.9
Median 21.0 16.0
Range 5.0–36.0 4.0–33.0
N2 8 2 8
Change From Baseline
Mean* 0.18 0.82 0.4921
SD 3.98 2.88
Median 0.00 1.00
Range 212.0–9.0 27.0–7.0
1= placebo group received matched placebo for both medications, L-carnitine
and VPA.
2=active treatment group received both L-carnitine and VPA.
MHFMS=Modified Hammersmith Functional Motor Scale Score (Range 0–40).
*Difference =0.643: Upper confidence level difference 2.505, Lower confidence
level difference 21.219.
doi:10.1371/journal.pone.0012140.t002
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Adverse events were elicited systematically via a full review of
systems at the time of each visit, and parents were instructed to
immediately report symptoms or illnesses occurring between visits
via telephone. Study coordinators also reviewed medical records
for emergency room or hospital visits. Adverse events were graded
using Common Terminology Criteria for Adverse Events v3.0
(CTCAE v3.0). An independent Data and Safety Monitoring
Committee provided oversight for the study.
Statistical Analysis
A prior open-label study of SMA type 2 subjects showed the
standard deviation for MHFMS-SMA was 3.19. [27] A clinically
meaningful change was estimated to be a 3 point change in
MHFMS-SMA at 6 months. A sample size of 25 subjects
completing both the baseline and six-month evaluations provided
at least 90% statistical power with an effect size of 0.941, Type I
error of 0.05 (two-sided). Assuming 20% attrition then 60 total
subjects were required. Subjects were randomized using a
permuted block design with blocks of size 6 with no stratification.
The statistician for the study (author CS) created a blinded
randomization list using the permuted block algorithm. At the
second screening visit the site determines whether the subject was
eligible, then completed a randomization request form that was
faxed to one of the authors (CS) who would assign the subject per
the predetermined randomization list. The treatment assignment
was then sent to the central pharmacy to dispense the study
medication. The statistician was blinded to treatment assignment,
as was the study coordinator, treating investigator, patient and
parents.
The assumption of normality for continuous variables was
examined using the Shapiro-Wilks tests. Fisher’s exact test was
used to compare treatment groups in the analysis of categorical
variables (e.g., gender). Baseline demographics and function were
analyzed as continuous variables with treatment groups compared
using a t-test. Analysis of variance (ANOVA) test was used to
compare treatment groups for change from baseline data when
Table 3. MHFMS - Change from baseline to 12 months (Phases I and II).
Group 1 Placebo Phase I* CARNI-VAL
Phase II**
Group 2 CARNI-VAL Phase I* CARNI-VAL
Phase II**
Endpoint N=28 N=30 p-value
Last Screen Value (S2)
Mean 20.0 16.6
SD 9.6 8.7
Median 17.5 16.5
Range 3.0–38.0 3.0–36.0
12 Month Visit (V3)
Mean 20.1 18.3 0.4039
SD 8.4 7.9
Median 19.5 18.0
Range 5.0–33.0 5.0–34.0
Change From Baseline
Mean*** 0.14 1.73 0.1845
SD 4.68 4.31
Median 0.00 2.00
Range 214.0–13.0 28.0–12.0
*Phase I = first six months treatment period in which subjects were randomized to receive either placebo for both VPA and L-carnitine or active treatment.
**Phase II = intention to treat period in which all subjects receive active treatment
MHFMS=Modified Hammersmith Functional Motor Scale Score (Range 0–40).
***Difference=1.591. Upper confidence level difference 3.962, Lower confidence level difference 20.782.
doi:10.1371/journal.pone.0012140.t003
Table 4. MHFMS within age groups by treatment arm –
change from baseline.
,3 years 3–8 years
Change from
Baseline Visit Placebo
1
CARNI-
VAL
2 Placebo
1
CARNI-
VAL
2
V1 (3 month visit) Phase I Phase I
N 1 11 0 2 01 8
Mean 1.18 0.90 0.45 1.06
SD 3.49 1.66 2.70 2.87
V2 (6 month visit) Phase I Phase I
N 1 11 2 1 71 8
Mean 1.09 1.33 20.41 0.44
SD 5.37 2.27 2.79 3.29
V3 (12 month visit) Phase II Phase II
N 1 11 2 1 71 8
Mean 2.09 2.92 21.11 0.94
SD 6.41 3.50 2.64 4.70
1= placebo group received matched placebo for both medications, L-carnitine
and VPA for the first six months (Phase I), followed by treatment with
L-carnitine and VPA the second six months (Phase II).
2=active treatment group received both L-carnitine and VPA for the full twelve
months.
MHFMS=Modified Hammersmith Functional Motor Scale Score.
doi:10.1371/journal.pone.0012140.t004
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data were not normally distributed then the Wilcoxon rank-sum
test was used (e.g., change in BMD). Linear regression analysis was
used to examine baseline characteristics, potential prognostic
factors for normally distributed outcome variables. The Pearson
Correlation Coefficient, calculated from the linear regression, was
used to assess association between continuous variables. Longitu-
dinal analysis was performed using generalized estimating
equations. When the data were normally distributed the identity
link function was used and unstructured correlation. We used the
small sample adjustment to the Score test, J/(J-1) where J is the
number of clusters [37] When both random and fixed effects were
analyzed, a mixed effect longitudinal analysis was performed. A p-
value less than 0.05 was considered statistically significant.
Reliability of the MHFMS in this group of subjects was evaluated
using the intraclass correlation coefficient (ICC). This was used to
determine the reliability across evaluators at different sites.
All analyses were performed on an intent-to-treat population
that was defined as all subjects randomized to receive study
medication. There were 61 subjects randomized, 4 subjects did not
have a 6-month data: 2 of these dropped out after the 3-month
visit, the other 2 missed their 6-month visit due to illness. At 12
months the 2 subjects missing the 6 month visit returned. MHFMS
was not performed in one additional patient at 6 months. At 12-
months one had a missing MHFMS. No data imputation was
performed. CMAP was not performed according to protocol at 2
of the clinical sites accounting for 17 missing values. Parent-proxy
QOL was not collected at the 6 month visit in 3 subjects.
Results
Recruitment began in September 2005 and enrollment of the
last subject was completed in October of 2006. The last subjects’
final visit was in November 2007, and database was locked in
March 2008. Participant flow is outlined in figure 1.
Baseline Characteristics of Study Population
The analysis of demographic data (Table 1) indicates that the 2
treatments were well balanced for most factors. More males were
enrolled in the placebo group (64.5%) and more females were
enrolled in the treatment group (56.7%) but overall, there was no
statistical difference (p=, 0.126). Body Mass Index (BMI)
assessments indicated no significant difference between treatment
arms (Supplemental Table S1). Total body BMD, BMC, lean mass
and fat mass prior to the start of treatment were assessed via
DEXA scans performed at three sites (Supplemental Table S2).
Baseline pulmonary function tests (PFTs) in subjects five years of
age and older and baseline CMAP values were equivalent across
groups (Supplemental Tables S3 and S4). Myometry data from
children five years of age and older indicated that upper extremity
strength was greater in the placebo group (Supplemental Table S5,
p#.03), but lower extremity myometry data demonstrated no
difference between groups. The PedsQL parent assessment
indicates no statistical difference between the placebo and
treatment group on any of the subscales, psychosocial or total
QOL (Supplemental Table S6). Only a subset of subjects was able
to complete their own PedsQL (Supplemental Table S7).
Reliability of the primary efficacy outcome measure,
MHFMS-SMA, during the screening period
We used the ICC to determine the reliability of MHFMS from
the first screening visit to the second, rated within their institution.
Evaluating all subjects, the reliability is 0.97. The reliability at each
institution was excellent and similar to the reliability previously
reported (0.95–0.99). [27,29]
Primary efficacy outcome
Impact of treatment on gross motor function as
measured via MHFMS. The primary endpoint was change
from baseline in the MHFMS score at 6 months. The distribution
of the change from baseline data was normally distributed. There
was no difference in change from baseline at 6 months between
placebo and treatment groups (p=0.492, Table 2). A linear
regression analysis for the change from baseline to 6 months of the
MHFMS, including age at study entry and treatment group as
independent variables, indicates that age has a borderline effect on
change (p=0.0564), but treatment was not significant at
Figure 3. Change from baseline fat mass versus the baseline fat mass by treatment arm.
doi:10.1371/journal.pone.0012140.g003
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that as age increases the change in MHFMS decreases. Thus,
subjects that were older at the start of the study had less of an
increase in scores than younger subjects. Gender was examined as
a possible independent variable but was excluded from the model
(p=0.92).
During the last six months, starting from V2, all subjects
received active treatment. There was no statistical difference in the
change from baseline between the two groups; however, for
subjects on treatment for the entire 12 months, there was a small
increase in the MHFMS score compared to baseline (Table 3,
p=0.185). Based upon the indication that age had a negative
relationship on MHFMS change over time, we investigated
splitting the subjects into two groups: over age three years and
under age three years. Generalized estimating equations were used
to examine the change from baseline MHFMS score over a 12
month period in children ages two to three years of age (n=23).
There was a negative effect of baseline weight over the 12 month
interval (estimate=20.81, p=0.0066) but a positive effect of
treatment over that period (estimate=1.21, p=0.03). Analysis of
children three years of age and older (n=33) demonstrated a
similar negative weight effect (estimate=20.16, p=0.0005)
without the apparent treatment effect (p=0.153). Table 4 displays
the change from baseline in MHFMS within each age group by
treatment arm. Subjects two to three years of age in the treatment
group have an increasing slope through each visit, indicating a
treatment benefit, while no such effect was observed in children
greater than 3 years.
Ancillary analyses
Impact of weight, BMI and body composition on primary
motor outcomes. The BMI z-score and BMI percent were
adjusted for subject age. BMI, BMI z-score and BMI percent were
available at each follow-up visit. A generalized estimating equation
analysis of change from baseline MHFMS indicated that
increasing BMI over the year of study was negatively associated
with outcome. BMI was treated as a time-varying covariate in
the generalized estimating equation model. As BMI increased
over time, change in MHFMS decreased (estimate=20.05,
p,0.0001). Linear regression analysis indicated that a change in
fat mass as measured by DEXA is negatively related to a change in
MHFMS (p=0.0409). As fat mass increases by the 6-month time-
point, MHFMS decreases. Figure 3 presents the change from
baseline fat mass versus the baseline fat mass by treatment arm
from the three sites that obtained DEXA measurements. BMI
percent based upon z-score correlated well with baseline fat mass
(correlation=0.475, p=0.0004). A regression analysis indicates
that as weight at baseline increases, change from baseline
MHFMS score worsens (p=0.0058).
Impact of treatment on bone density. The change in total
body BMD and BMC at 6 months was not normally distributed.
Table 5. CMAP values by treatment arm – 6 month values
and change from baseline.
Characteristic
Placebo
1
N=31
CARNIVAL
2
N=30
Total
N=61
Compound Muscle Action Potential Amplitude at 6 Months (CMAP, mV)
N1 9 1 9 3 8
Mean 2.32 2.37 2.34
SD 1.75 1.82 1.76
Median 1.44 1.80 1.73
Range 0.50–6.14 0.30–7.81 0.30–7.81
CMAP Amplitude Change from Baseline (mV)
N1 9 1 9 3 8
Mean* 20.10 0.02 20.04
SD 0.66 0.70 0.67
Median 0.06 0.20 0.08
Range 21.52–1.20 21.70–1.15 21.70–1.20
p-value (P vs C) 0.589
p-value (Change from Zero) 0.715
Compound Muscle Action Potential Area at 6 Months (CMAP, mVus)
N1 9 1 9 3 8
Mean** 5.28 5.26 5.27
SD 4.49 4.65 4.51
Median 3.74 3.40 3.52
CMAP Area Change from Baseline (mVus)
N1 9 1 9 3 8
Mean 20.64 20.07 20.36
SD 1.57 1.11 1.37
Median 20.35 0.10 20.15
Range 23.60–2.09 22.40–2.04 23.60–2.09
p-value (P vs.C) 0.2046
p-value (Change from Zero) 0.1138
1= placebo group received matched placebo for both medications, L-carnitine
and VPA.
2=active treatment group received both L-carnitine and VPA.
*Difference =0.121. Upper confidence level difference 0.568. Lower confidence
level difference 20.328.
**Difference =0.570. Upper confidence level difference 1.465. Lower
confidence level difference 20.326.
doi:10.1371/journal.pone.0012140.t005
Figure 4. Scatterplot matrix demonstrating correlation be-
tween maximum CMAP negative peak amplitude and MHFMS
scores with 95% density ellipse. Correlation =0.5643. The red lines
are 95% confidence bands. Note that the majority of the data are
contained in the linear relationship between these two factors with only
one outlier.
doi:10.1371/journal.pone.0012140.g004
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the change in BMD (p=0.82) or BMC (p=0.41).
Impact of age on primary motor outcome. As subjects get
older, their weight increases, and the relationship between weight
and age causes a multi-colinearity problem in the analysis.
However, linear regression analysis of change in MHFMS and
age as the only independent predictor indicated that age is
statistically significant at p=0.0069. The coefficient for age is
20.62 (SE 0.219) indicating that as age increases the change in
MHFMS score decreases.
Impact of treatment on electrophysiologic measures of
innervation. There was no significant change in CMAP
negative peak amplitude or area measurements between
treatment groups after 6 months (Table 5). However, there was
a good correlation between maximum CMAP amplitude and our
primary outcome measure, the MHFMS (figure 4).
Impact of treatment on quality of life outcome
assessments. Quality of life was measured using the PedsQL.
There were no statistically significant differences between
treatment groups for the parent-proxy QOL at 6 months
(Table 6). The parent-proxy total QOL was compared to
significant change (3 point change) in MHFMS at 6 months.
Total QOL did not improve as MHFMS improved, but there was
evidence of deterioration in QOL as MHFMS declined (Table 7).
Impact of treatment on myometry measurements.
Myometry was assessed in fifteen subjects at least 5 years of age
whose assessments were not limited by contractures. Tables 8 and
9 present the 6 month and change from baseline data for upper
and lower extremity strength assessments. There were no
statistically significant differences between the two treatment
groups (Table 10).
At 12 months, there were no statistically significant differences
between groups initially assigned to placebo or to treatment. In the
group receiving treatment for the full year, there was no continual
improvement over the second six-month treatment period (data
not shown). A generalized estimating equation model indicates
that there is no period by arm effect (p=0.73) and no BMI effect
(p=0.7983).
Impact of treatment on pulmonary function. PFTs were
performed only in subjects five years of age and older (n=24), thus
limiting the power to observe any relationship with treatment.
Treatment was not associated with changes in any of the PFT
outcomes over the treatment period (data not shown).
Impact of treatment on quantitative measures of SMN
mRNA in whole blood. Results of mRNA analysis at 6 months
are in Table 11. There was no difference in actual baseline values
or change from baseline values between the 2 treatment groups at
6 months. In addition, no difference was apparent between
treatment groups through 12 months for either flSMN or D7
SMN. A mixed effect model analysis over the entire year indicated
that baseline flSMN was highly predictive of flSMN at one year
(p,0.0001), indicating very little change in flSMN. The
correlation between D7 SMN baseline and D7 SMN at one year
was less than flSMN, but still highly significant (p,0.0001). The
minimal change over time and lack of correlation with baseline
function provides little indication of a relationship between these
mRNA parameters and outcome measures.
Table 6. Parent-proxy assessment of quality of life (PedsQL)
by treatment arm 26 month values and change from
baseline.
Placebo
1 CARNIVAL
2 Total
Characteristic N=31 N=30 N=61
School Functioning 6 Month Value
N2 3 2 2 4 5
Mean 64.6 59.8 62.3
SD 16.8 16.0 16.4
Median 60 60 60
Range 16.7–100 0–80 0–100
School Functioning Change from Baseline
N1 9 2 1 4 0
Mean 22.1 28.9 25.7
SD 22.7 13.8 18.6
Median 0 25 25
Range 250–35 250–8.3 250–35
Psychosocial Summary 6 Month Value
N2 7 2 7 5 4
Mean 68.2 66.1 67.2
SD 12.2 12.0 12.0
Median 66.7 68.2 67.4
Range 43.2–88.6 27.3–81.2 27.3–88.6
Psychosocial Summary Change from Baseline
N2 7 2 7 5 4
Mean 0.2 2.5 21.2
SD 14.4 13.0 13.7
Median 0.8 0 0.4
Range 231.6–31.8 250–15.6 250–31.8
Total QOL 6 Month Value
N2 7 2 7 5 4
Mean 55.0 50.6 52.8
SD 14.5 10.2 12.6
Median 51.2 51.7 51.5
Range 29.2–85 22.2–73.1 22.2–85
Total QOL Change from Baseline
N2 7 2 7 5 4
Mean 0.3 21.9 20.8
SD 12.9 13.6 13.1
Median 3.6 21.2 0.8
Range 232.2–31.9 233.1–18.1 233.1–31.9
1= placebo group received matched placebo for both medications, L-carnitine
and VPA.
2=active treatment group received both L-carnitine and VPA.
QOL=Quality of Life.
doi:10.1371/journal.pone.0012140.t006
Table 7. MHFMS 3-point response and average parent-proxy
total QOL - change from baseline to 6 months.
Level Number Mean SD
Decline 7 23.4127 10.2912
Stable 34 20.7391 14.7807
Response 13 0.2991 10.1477
MHFMS=Modified Hammersmith Functional Motor Scale Score.
doi:10.1371/journal.pone.0012140.t007
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Eight participants (13%) were less than fully compliant with
recommended VPA dosing, and eight participants (13%) were less
than fully compliant with carnitine during one or more study visits
during phase 1. Mean overnight VPA trough level in Group 2
(subjects receiving treatment) during phase 1 was 58.5 +/2 63.3
SD (16.8 to 101.0, range), which falls within the targeted trough
level range of 50–100 mg/dL. VPA levels at 6 months were not
associated with change in MHFMS.
Adverse Events
Adverseeventsoccurred in58% ofthosereceivingplacebo and in
77% of treated subjects during the randomized treatment phase.
Although there were no statistically significant differences between
Table 8. Myometry of upper extremity by treatment arm – 6
month values and change from baseline.
Placebo
1 CARNIVAL
2
Characteristic N=31 N=30
Right Elbow 6 Month Value
(kg)
N7 8
Mean 2.17 1.55
SD 1.24 0.56
Median 1.45 1.35
Range 1.20–4.17 0.98–2.72
Right Elbow Change from Baseline (kg)
N7 7
Mean 20.04 0.41
SD 0.45 0.45
Median 20.07 0.40
Range 20.87–0.53 20.25–0.97
Left Elbow 6 Month Value (kg)
N7 8
Mean 2.21 1.47
SD 1.31 0.42
Median 1.65 1.50
Range 0.95–4.30 0.83–2.23
Left Elbow Change from Baseline (kg)
N7 7
Mean 0.11 0.22
SD 0.65 0.33
Median 0.02 0.21
Range 21.12–0.99 20.17–0.83
Upper Extremity 6 Month Value (kg)
N7 8
Mean 4.38 3.02
SD 2.53 0.94
Median 3.10 2.88
Range 2.15–8.07 1.81–4.96
Upper Extremity Change from Baseline (kg)
N7 7
Mean* 0.07 0.64
SD 1.04 0.60
Median 20.04 0.61
Range 21.99–1.03 0.01–1.81
1= placebo group received matched placebo for both medications, L-carnitine
and VPA.
2=active treatment group received both L-carnitine and VPA.
*Difference =0.566. Upper confidence level difference 1.581. Lower confidence
level difference 20.450.
doi:10.1371/journal.pone.0012140.t008
Table 9. Myometry of lower extremity by treatment arm - 6
month values and change from baseline.
Placebo
1 CARNIVAL
2
Characteristic N=31 N=30
Right Knee 6 Month Value (kg)
N6 7
Mean 0.87 1.00
SD 0.42 0.77
Median 0.84 1.13
Range 0.40–1.47 0.00–2.0
Right Knee Change from Baseline (kg)
N4 6
Mean 20.39 0.24
SD 1.13 0.40
Median 20.05 0.18
Range 22.0–0.54 20.2–0.9
Left Knee 6 Month Value (kg)
N6 8
Mean 0.78 1.02
SD 0.41 0.60
Median 0.72 0.90
Range 0.40–1.50 0.20–1.77
Left Knee Change from Baseline (kg)
N4 6
Mean 20.46 0.31
SD 1.11 0.45
Median 0.07 0.17
Range 22.13–0.14 20.20–1.03
Lower Extremity 6 Month Value (kg)
N6 8
Mean 1.65 1.90
SD 0.82 1.38
Median 1.57 1.67
Range 0.85–2.97 0.20–3.77
Lower Extremity Change from Baseline (kg)
N4 6
Mean* 20.85 0.55
SD 2.22 0.83
Median 0.37 0.26
Range 24.13–0.64 20.27–1.93
1= placebo group received matched placebo for both medications, L-carnitine
and VPA.
2=active treatment group received both L-carnitine and VPA.
*Difference =1.40. Upper confidence level difference is 4.79, Lower confidence
level difference is 21.98.
doi:10.1371/journal.pone.0012140.t009
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reporting adverse events, serious adverse events, treatment-related
adverse events, and severe adverse events were all greater in the
treatment group (Table 12). A detailed listing of all adverse events
during the treatment phase is presented in Supplemental Table S8.
Gastrointestinal symptoms and respiratory symptoms were more
frequent in the treatment group. Four subjects (13%) on active
treatment had a severe adverse event, most commonly pneumonia
(Table 13). Treatment-related adverse events were nearly equal
between groups. There was no pattern in the placebo group, while
gastrointestinal AE were the most common in the treatment group.
Overall adverse events for the entire 12- month period in each
treatment group are presented in Supplemental Table S9.
Discussion
We chose to perform a placebo-controlled study of VPA in non-
ambulatory children with SMA based on encouraging preliminary
observations of improved motor function during an open label
study [27]. Our choice to target children ages 2–8 years reflected a
compromise between concerns regarding the lower limit of age
where reliable assessment of motor function was possible versus
concerns that improvement in older children may be constrained
by other factors that would confound assessment of an SMN-
enhanced treatment effect. A combined treatment regimen of VPA
and carnitine was selected to avoid a potential confounding effect
of carnitine depletion, because we had previously demonstrated an
apparent susceptibility for more rapid depletion of carnitine with
VPA treatment in this population. [27] Overall, enrollment was
targeted towards a more homogeneous younger cohort of subjects
who theoretically might be more likely to respond to therapy.
We did not detect a statistically significant improvement after
six months of treatment in our primary outcome measure - the
change in overall gross motor function assessed with the MHFMS.
In addition, we did not detect a significant change in secondary
endpoints of strength and function, which included assessment of
maximum upper and lower extremity strength via hand-held
myometry and PFTs. Adverse event frequency, although not
statistically different between groups, was somewhat higher in the
treatment group, particularly with regard to gastrointestinal and
respiratory symptoms. Although we did not observe any clinical or
laboratory evidence of serious hematologic or hepatic toxicity in
this study, excessive weight gain was clearly more prevalent in the
active treatment group. DEXA measurements confirmed that the
associated weight gain was due largely to an increase in total body
fat mass in the absence of an increase in lean mass.
Given the increased fat mass in the treatment group compared
to the placebo group during the phase 1 period, it is notable that
we did not observe a decline in gross motor function in the
treatment group as a whole. As in the open label study [27], weight
gain was not uniform across the population. Non-ambulatory
subjects greater than five years of age, and those having a higher
BMI at baseline, were at greatest risk. Children with the greatest
improvement in gross motor function as assessed by the MHFMS
gained less fat mass than did those with stable or worsening
MHFMS scores. The fact that the MHFMS did not decline in
light of substantial weight gain in the active treatment group
suggests that VPA may indeed have a modest yet measurable
biologic effect that is outweighed by its confounding effect of
weight gain. Increases in fat mass may not always be deleterious in
this population, where both over- and under-nourished states are
Table 10. Total myometry by treatment arm - 6 month values
and change from baseline.
Placebo CARNIVAL
Characteristic N=31 N=30
Total Myometry 6 Month Value (kilograms)
N8 8
Mean 5.07 4.92
SD 2.91 2.04
Median 4.52 4.60
Range 1.27–10.14 2.87–8.72
Total Myometry Change from Baseline (kilograms)
N8 7
Mean* 20.25 1.18
SD 2.47 0.91
Median 0.65 0.70
Range 26.12–1.41 0.52–2.91
1= placebo group received matched placebo for both medications, L-carnitine
and VPA.
2=active treatment group received both L-carnitine and VPA.
*Difference =1.431. Upper confidence level difference 3.550. Lower confidence
level difference 20.689.
doi:10.1371/journal.pone.0012140.t010
Table 11. SMN mRNA by treatment arm - 6 month values
and change from baseline.
Placebo
1
CARNI-
VAL
2
p-
value
flSMN N 22 18
Mean 2.01 2.47 0.31
SD 1.13 1.67
Min 0.58 0.53
Max 5.87 6.04
D7S M N N 2 2 1 8
Mean 6.76 7.02 0.43
SD 1.02 1.04
Min 4.49 4.92
Max 8.42 8.34
Change from baseline flSMN N 22 18
Mean 0.00 0.03 0.62
SD 0.11 0.22
Min 20.20 20.37
Max 0.21 0.62
Change from
baseline D7S M N
N2 2 1 8
Mean 20.09 0.03 0.62
SD 0.82 0.81
Min 22.19 21.22
Max 1.78 2.56
1= placebo group received matched placebo for both medications, L-carnitine
and VPA.
2=active treatment group received both L-carnitine and VPA.
SMN=Survival Motor Neuron, flSMN= Full-length survival motor neuron mRNA
levels, D7SMN=delta 7 SMN (missing exon 7) survival motor neuron mRNA
levels.
doi:10.1371/journal.pone.0012140.t011
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nutritional intake stimulated by an effect of VPA on appetite,
perhaps putting them into a more favorable anabolic state.
However, in other cases, due to increased gastrointestinal
symptoms related to VPA and/or L-carnitine, weight loss could
be a negative confounding factor.
Although no treatment effect was detected in the primary
outcome measure as assessed by the MHFMS, a post hoc analysis
demonstrated a statistically significant benefit in the youngest
cohort of children, those two to three years of age. In addition,
individuals who received the active treatment over a full year
showed modestly improved function, gaining just over 2 points on
the MHFMS, although this did not reach statistical or obvious
functional significance. Age proved to be a significant factor as to
whether or not subjects demonstrated an increase in MHFMS
scores in association with treatment. We have previously
demonstrated that increased age is associated with increased
severity of denervation, so it is not surprising that the youngest
non-ambulatory SMA children appear more likely to demonstrate
a benefit with intervention [12]. Duration of treatment also
appeared to be a factor and will need to be carefully considered in
the design of future clinical trials in non-ambulatory SMA subjects.
The ideal trial duration clearly depends on the expected
mechanism of the treatment to be studied and relies heavily on
the primary outcome measure chosen. This study affirms the value
of the MHFMS in the multicenter pediatric clinical trial setting as
a simple, reliable and easy to use outcome measure for
documenting gross motor function in children as young as two
years of age. However, if reinnervation is considered the most
likely mechanism for a given therapeutic intervention, a trial
duration of at least one year or longer may be more ideal to prove
a treatment benefit using the MHFMS.
Possible disease-related biomarkers assessed in this study
included quantitative SMN mRNA and maximum ulnar CMAP.
Levels of flSMN and D7 SMN mRNA did not change with VPA.
In contrast, VPA-response has been observed in SMA patient cell
lines (16,17), one-third of SMA subjects (18) and in spinal cord of
type III-like SMA mice (24). This result suggests that SMN
Table 13. Severe adverse events during Phase 1 by treatment group.
System Organ Class/Preferred Term (MedDRA) Placebo
1 N=31 n (%) CARNI-VAL
2 N=30 n (%)
Gastrointestinal Disorders 0( 0 ) 2( 7 )
Vomiting 0( 0 ) 2( 7 )
General Disorders and Administration Site Conditions 0( 0 ) 2( 7 )
Pyrexia 0( 0 ) 2( 7 )
Infections and Infestations 1( 3 ) 1( 3 )
Upper Respiratory Infection 1 (3) 0 (0)
Pneumonitis 0( 0 ) 1( 3 )
Respiratory, Thoracic and Mediastinal Disorders 0 (0) 5 (17)
Cough 0( 0 ) 1( 3 )
Pneumonia 0 (0) 3 (10)
Tachypnoea 0( 0 ) 1( 3 )
Nasal Congestion 0 (0) 1 (3)
Metabolism and Nutrition Disorders 0( 0 ) 1( 3 )
Dehydration 0( 0 ) 1( 3 )
1= placebo group received matched placebo for both medications, L-carnitine and VPA.
2=active treatment group received both L-carnitine and VPA.
medDRA=Medical Dictionary for Regulatory Activities.
doi:10.1371/journal.pone.0012140.t013
Table 12. Overall crude incidence of adverse events by treatment arm - baseline to 6 months (Phase I).*
Group 1 Placebo
1 Group 2 CARNI-VAL
2
Endpoint N=31 (%) N=30 (%) p-value
Subjects Reporting $ One Adverse Event 18 (58) 23 (77) 0.1737
Subjects Reporting $ One SAE 1 (3) 4 (13) 0.1953
Subjects Reporting $ One Treatment-Related Adverse Event 9 (29) 11 (36) 0.5921
Subjects Reporting $ One Severe AE 2 (6) 6 (20) 0.1466
Subjects Reporting $ One Treatment-Related SAE 0 (0) 0 (0)
1= placebo group received matched placebo for both medications, L-carnitine and VPA.
2=active treatment group received both L-carnitine and VPA.
SAE=Serious Adverse Event.
*Relative risks (RR) are as follows for the categories included in this table: RR for 1 AE =1.32 (0.92, 1.89); RR for 1SAE =4.13 (0.49,34.89); RR for 1 treatment-related AE
=1.26 (0.61,2.60); RR for 1 severe AE =3.10 (0.68, 14.17).
doi:10.1371/journal.pone.0012140.t012
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track VPA response. Because VPA targets are not specific, VPA
response in SMA subjects may be much more complex than
simply altering SMN expression. Indeed, recent data in a mild
SMA model suggests that VPA may function by increasing SMN
mRNA and protein, decreasing apoptosis and enhancing neuro-
protection (24). Alternatively, whole blood may not be the
appropriate cell type to detect changes in SMN expression, or
such changes may be too small to be detected by relative
quantification that relies on endogenous controls to normalize
data. Finally, the assay we used has limitations, because it is not
based on absolute quantification of SMN mRNA.
The strength of correlation between maximum CMAP
amplitude and our primary outcome measure, the MHFMS,
suggests that in non-ambulatory patients with SMA the CMAP
may be a robust surrogate outcome measure for assessing
treatment interventions if the putative mechanism of effect is to
enhance innervated muscle mass by reinnervation or other trophic
effects on nerve or muscle. However, baseline severity of
denervation overall in a given cohort will profoundly impact
whether or not improvement is anticipated and should be a key
consideration in any trial design incorporating this as an outcome
measure, as ceiling and floor effects may limit the usefulness of this
assay in those of greater or lesser strength or age.
In summary, this study demonstrated no benefit from six months
of treatment with VPA and L-carnitine in a young non-ambulatory
cohort of subjects with SMA. Any modest biologic impact of VPA
on individual outcome measures over the duration of treatment in
this study was clearly outweighed by weight gain. This trial
confirmed observations made in the open label study that the effects
of age and weight gain with VPA are critical confounding factors
that will have to be considered in the design of future clinical trials.
Whether or not a subset of younger non-ambulatory SMA subjects
might benefit from VPA treatment early in the course of their
disease over a longer treatment period remains an outstanding
question. Treatment intervention with VPA in non-ambulatory
SMA children outside of a clinical study should be discouraged
given the lack of clear benefit from this trial, and the potentially
serious adverse events associated with VPA treatment. However,
these results should be interpreted in the context of the limited
treatment duration examined, an issue which should be carefully
considered in the design of future clinical trials based on proposed
mechanism of therapeutic action. We anxiously await the
completion of ongoing studies of VPA in an ambulatory adult
population (the VALIANT trial, clinicaltrials.gov ID
NCT00481013) to help us further expand our knowledge about
possible biologic impact of VPA in subjects with SMA. The ability
to obtainstrength data from the entire cohortin the VALIANTtrial
should help to answer outstanding questions about potential
biologic effects of VPA in subjects with SMA, and whether this
agent merits further study as a therapeutic agent in this disorder.
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